Outcome of Parkinson's Disease Patients Affected by <scp>COVID</scp>‐19

Antonini, Angelo; Leta, Valentina; Teo, James; Chaudhuri, K. Ray

doi:10.1002/mds.28104

Cited by 215 publications

(359 citation statements)

References 9 publications

Supporting

Mentioning

330

Contrasting

Unclassified

Order By: Relevance

“…The full-text screening of these studies led to the exclusion of 286 that did not meet the inclusion criteria. The remaining 26 studies were identified as eligible to be reviewed [ 6 , 7 , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] ]. Fig.…”

Section: Resultsmentioning

confidence: 99%

“…A few cohort studies have shown that patients with preexisting neurological disorders who contracted COVID-19 developed more severe clinical symptoms and worse outcomes, compared to the general population [ 4 , 5 ]. In addition, patients with neurological disorders such as Parkinson’s disease and dementia who developed COVID-19 had a worsening of preexisting neurological symptoms [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review

Kubota

Kuroda

2021

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

Highlights COVID-19 effects were studied in patients with comorbid neurological disorder. This review included 26 reports of comorbid neurological disorder and COVID-19. Papers were identified from the MEDLINE (PubMed) and medRxiv databases. Overall, 22.0 % of patients had severe COVID-19 course. Notably, 31.9 % of patients experienced an exacerbation of preexisting neurological symptoms.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review

Kubota

Kuroda

2021

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

show abstract

“…We and others have previously flagged concerns regarding COVID-19 in people with Parkinson's disease (PD), especially for older and frail subjects with advanced PD who may be particularly vulnerable 45,46 .…”

Section: Symptomsmentioning

confidence: 99%

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

Sulzer

Antonini

Leta

et al. 2020

npj Parkinsons Dis.

Self Cite

142

165

View full text Add to dashboard Cite

This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus on Parkinson's disease. Major points include that neuropathology studies have not answered the central issue of whether the virus enters central nervous system neurons, astrocytes or microglia, and the brain vascular cell types that express virus have not yet been identified. Currently, there is no clear evidence for human neuronal or astrocyte expression of angiotensin-converting enzyme 2 (ACE2), the major receptor for viral entry, but ACE2 expression may be activated by inflammation, and a comparison of healthy and infected brains is important. In contrast to the 1918 influenza pandemic and avian flu, reports of encephalopathy in COVID-19 have been slow to emerge, and there are so far no documented reports of parkinsonism apart from a single case report. We recommend consensus guidelines for the clinical treatment of Parkinson's patients with COVID-19. While a role for the virus in causing or exacerbating Parkinson's disease appears unlikely at this time, aggravation of specific motor and non-motor symptoms has been reported, and it will be important to monitor subjects after recovery, particularly for those with persisting hyposmia.

show abstract

“…These include older adults and those with pre-existing medical conditions (chronic kidney disease, chronic obstructive pulmonary disease, obesity, serious cardiovascular disease, severe immunocompromised state, type 2 diabetes, sickle cell anemia, and frailty), or both [32][33][34][35][36][37]. An additional possibility is that people-with-Parkinson's (PwP) would be at increased risk of worse outcomes from COVID-19 since PD is more common in older adults, and PwP can have compromised respiratory and immune states [38][39][40].…”

Section: A Potential Sinister Predicament Includes Parkinson's Diseasmentioning

confidence: 99%

Exercise for Older Adults Improves the Quality of Life in Parkinson’s Disease and Potentially Enhances the Immune Response to COVID-19

Hall

Church

2020

Brain Sciences

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disorder brought about due to dopaminergic neuronal cell loss in the midbrain substantia nigra pars compacta region. PD presents most commonly in older adults and is a disorder of both motor and nonmotor dysfunction. The novel SARS-CoV-2 virus is responsible for the recent COVID-19 pandemic, and older individuals, those with preexisting medical conditions, or both have an increased risk of developing COVID-19 with more severe outcomes. People-with-Parkinson’s (PwP) of advanced age can have both immune and autonomic nervous problems that potentially lead to pre-existing pulmonary dysfunction and higher infection risk, increasing the probability of contracting COVID-19. A lifestyle change involving moderate-intensity exercise has the potential to protect against SARS-CoV-2 through strengthening the immune system. In addition to a potential protective measure against SARS-CoV-2, exercise has been shown to improve quality-of-life (QoL) in PD patients. Recent studies provide evidence of exercise as both neuroprotective and neuroplastic. This article is a literature review investigating the role exercise plays in modifying the immune system, improving health outcomes in PwP, and potentially acting as a protective measure against SARS-Cov-2 infection. We conclude that exercise, when correctly performed, improves QoL and outcomes in PwP, and that the enhanced immune response from moderate-intensity exercise could potentially offer additional protection against COVID-19.

show abstract

Outcome of Parkinson's Disease Patients Affected by COVID‐19

Cited by 215 publications

References 9 publications

Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review

Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

Exercise for Older Adults Improves the Quality of Life in Parkinson’s Disease and Potentially Enhances the Immune Response to COVID-19

Contact Info

Product

Resources

About